1-20 of 42
Joseph D. Rosenblatt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma

Juan Pablo Alderuccio, Alvaro J Alencar, Jonathan H. Schatz, Russ Kuker, David Sicre, Georgios Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Michele D. Stanchina, Asaad Trabolsi, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz
Journal: Blood
Blood (2024) 144 (Supplement 1): 337.
https://doi.org/10.1182/blood-2024-199093
Published: 2024
Journal Articles

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jacob Wulff, Rhine Shen, Wangshu Zhang, Soumya Poddar, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2024) 144 (Supplement 1): 864.
https://doi.org/10.1182/blood-2024-194627
Published: 2024
Journal Articles

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Juan Pablo Alderuccio, Alvaro J. Alencar, Jonathan H. Schatz, Russ Kuker, Georgio Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Nathalie Padron, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz
Journal: Blood
Blood (2023) 142 (Supplement 1): 984.
https://doi.org/10.1182/blood-2023-178825
Published: 2023
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew Ulrickson, Emanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Jiali Yan, Qinghua Song, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Harry Miao, Sara Beygi, Caron A. Jacobson
Journal: Blood
Blood (2022) 140 (Supplement 1): 10380–10383.
https://doi.org/10.1182/blood-2022-156120
Published: 2022
Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Marika Sherman, Jinghui Dong, Alessandro Giovanetti, Yin Yang, Christine Lui, Zahid Bashir, A Scott Jung, Caron Jacobson
Journal: Blood
Blood (2021) 138 (Supplement 1): 93.
https://doi.org/10.1182/blood-2021-148473
Published: 2021
Journal Articles

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Caron Jacobson, MD MMSc, Julio C. Chavez, MD, Alison R. Sehgal, MD, Basem M. William, MDMRCP, Javier Munoz, MD, Gilles Salles, MDPhD, Pashna N. Munshi, MD, Carla Casulo, MD, David Maloney, MD PhD, Sven de Vos, MD PhD, Ran Reshef, MD, Lori A. Leslie, MD, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, MBBS, MPH, Henry C.H. Fung, MD, Joseph D. Rosenblatt, MD, John M. Rossi, MS, Lovely Goyal, PhD, Vicki Plaks, LLB, PhD, Yin Yang, MS, Jennifer Lee, BS, Wayne Godfrey, MD, Remus Vezan, MD PhD, Mauro P. Avanzi, MD PhD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136834
Published: 2020
Journal Articles

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Juan Pablo Alderuccio, MD, Sunil Iyer, MD, Isildinha M Reis, PhD, Alvaro J. Alencar, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3992.
https://doi.org/10.1182/blood-2019-125004
Published: 2019
Journal Articles

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

Clinical Trials & Observations
Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov
Journal: Blood
Blood (2017) 130 (25): 2709–2717.
https://doi.org/10.1182/blood-2017-05-780049
Published: 2017
Includes: Supplemental data
Journal Articles

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell–dependent cytotoxicity

Shruti Bhatt, Salma Parvin, Yu Zhang, Hyun-Mi Cho, Kranthi Kunkalla, Francisco Vega, John M. Timmerman, Seung-Uon Shin, Joseph D. Rosenblatt, Izidore S. Lossos
Journal: Blood
Blood (2017) 129 (16): 2246–2256.
https://doi.org/10.1182/blood-2016-09-738211
Published: 2017
Includes: Supplemental data
Journal Articles

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H Advani, MD, Pauline Brice, MD, Nancy L Bartlett, MD, Joseph D Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A Fanale, MD, Joseph M. Connors, Keenan Fenton, Dirk Huebner, MD, Juan Pinelli, Andrei R. Shustov
Journal: Blood
Blood (2016) 128 (22): 4144.
https://doi.org/10.1182/blood.V128.22.4144.4144
Published: 2016
Journal Articles

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations Brief Report
Robert Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dirk Huebner, Abraham Fong, Anas Younes
Journal: Blood
Blood (2016) 128 (12): 1562–1566.
https://doi.org/10.1182/blood-2016-02-699850
Published: 2016
Includes: Supplemental data
Journal Articles

Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma

Robert Chen, Ajay K. Gopal, MD, Scott E. Smith, Stephen Ansell, MD PhD, Joseph D. Rosenblatt, Kerry J. Savage, MDMSc, Joseph M. Connors, MD, Andreas Engert, Emily K Larsen, Dirk Huebner, Abraham Fong, Anas Younes, MD
Journal: Blood
Blood (2015) 126 (23): 2736.
https://doi.org/10.1182/blood.V126.23.2736.2736
Published: 2015
Journal Articles

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Ajay K. Gopal, Robert Chen, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Xuedong Chi, Eric L. Sievers, Anas Younes
Journal: Blood
Blood (2015) 125 (8): 1236–1243.
https://doi.org/10.1182/blood-2014-08-595801
Published: 2015
Includes: Supplemental data
Journal Articles

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, Jeffrey Matous, MD, Radhakrishnan Ramchandern, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yinghui Wang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, BCOP, Andrei R. Shustov, MD
Journal: Blood
Blood (2014) 124 (21): 3095.
https://doi.org/10.1182/blood.V124.21.3095.3095
Published: 2014
Journal Articles

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Jesus C Fabregas, MD, James E. Hoffman, MD, Tulay Koru-Sengul, PhD, Miao Feng, Deborah Goodman, Aldo Serafini, MD, Peter J Hosein, MD, Alexandra Stefanovic, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD
Journal: Blood
Blood (2014) 124 (21): 1762.
https://doi.org/10.1182/blood.V124.21.1762.1762
Published: 2014
Journal Articles

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dirk Huebner, MD, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD
Journal: Blood
Blood (2013) 122 (21): 1809.
https://doi.org/10.1182/blood.V122.21.1809.1809
Published: 2013
Journal Articles

Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Ajay K. Gopal, MD, Robert Chen, MD, Scott E. Smith, MD, PhD, Stephen M Ansell, M.D.Ph.D., Joseph D Rosenblatt, MD, Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Andreas Engert, MD, Emily K. Larsen, MS, Dirk Huebner, MD, Eric L. Sievers, MD, Anas Younes, MD
Journal: Blood
Blood (2013) 122 (21): 4382.
https://doi.org/10.1182/blood.V122.21.4382.4382
Published: 2013
Journal Articles

Targeting B-Cell Malignancies With Anti-CD20-Interleukin-21 Fusokine

Shruti Bhatt, MS, Daxing Zhu, MD, Xiaoyu Jiang, PhD, Seung-uon Shin, PhD, John M Timmerman, MD, Joseph D. Rosenblatt, MD, Izidore S Lossos, MD
Journal: Blood
Blood (2013) 122 (21): 377.
https://doi.org/10.1182/blood.V122.21.377.377
Published: 2013
Journal Articles

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

Barbara Pro, MD, Ranjana H. Advani, MD, Pauline Brice, MD, Nancy L. Bartlett, MD, Joseph D. Rosenblatt, MD, Tim Illidge, PhD, Jeffrey V. Matous, MD, Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Joseph M. Connors, MD, Yin Yang, MS, Dana A. Kennedy, PharmD, Andrei R. Shustov, MD
Journal: Blood
Blood (2012) 120 (21): 2745.
https://doi.org/10.1182/blood.V120.21.2745.2745
Published: 2012